These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18664987)

  • 21. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
    Hirsch MS; Günthard HF; Schapiro JM; Brun-Vézinet F; Clotet B; Hammer SM; Johnson VA; Kuritzkes DR; Mellors JW; Pillay D; Yeni PG; Jacobsen DM; Richman DD
    Clin Infect Dis; 2008 Jul; 47(2):266-85. PubMed ID: 18549313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV transmitted drug resistance in adult and pediatric populations in Panama.
    Castillo J; Arteaga G; Mendoza Y; Martínez AA; Samaniego R; Estripeaut D; Page KR; Smith RE; Sosa N; Pascale JM
    Rev Panam Salud Publica; 2011 Dec; 30(6):649-56. PubMed ID: 22358417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure.
    Briones C; Soriano V; González-Lahoz J
    AIDS; 2000 Jul; 14(11):1659-60. PubMed ID: 10983655
    [No Abstract]   [Full Text] [Related]  

  • 24. [The newest developments in anti-HIV-1 drugs].
    Zhang XQ
    Yao Xue Xue Bao; 2010 Feb; 45(2):194-204. PubMed ID: 21351429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 26. Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches.
    Shet A; Markowitz M
    Curr Opin Investig Drugs; 2006 Aug; 7(8):709-20. PubMed ID: 16955682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).
    Zolopa AR; Lazzeroni LC; Rinehart A; Vezinet FB; Clavel F; Collier A; Conway B; Gulick RM; Holodniy M; Perno CF; Shafer RW; Richman DD; Wainberg MA; Kuritzkes DR
    Clin Infect Dis; 2005 Jul; 41(1):92-9. PubMed ID: 15937768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2019 update of the drug resistance mutations in HIV-1.
    Wensing AM; Calvez V; Ceccherini-Silberstein F; Charpentier C; Günthard HF; Paredes R; Shafer RW; Richman DD
    Top Antivir Med; 2019 Sep; 27(3):111-121. PubMed ID: 31634862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois.
    Kuritzkes DR
    HIV Clin Trials; 2001; 2(3):219-26. PubMed ID: 11590531
    [No Abstract]   [Full Text] [Related]  

  • 31. Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
    Garcia F; Alvarez M; Fox Z; Garcia-Diaz A; Guillot V; Johnson M; Chueca N; Phillips A; Hernández-Quero J; Geretti AM
    Antivir Ther; 2011; 16(3):373-82. PubMed ID: 21555820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 33. Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02_AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Côte d'Ivoire.
    Adjé-Touré C; Bilé CE; Borget MY; Hertog K; Maurice C; Nolan ML; Nkengasong JN
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):111-3. PubMed ID: 14501802
    [No Abstract]   [Full Text] [Related]  

  • 34. HIV-1 drug resistance in newly infected individuals.
    Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
    JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.
    Xu W; Wang Q; Yu F; Lu L; Jiang S
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):1-6. PubMed ID: 24977378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of drug resistance assays in testing HIV-1 non-B subtypes.
    Holguín A; Hertogs K; Soriano V
    Clin Microbiol Infect; 2003 Apr; 9(4):323-6. PubMed ID: 12667245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Basic approaches to anti-HIV resistance].
    Baba M
    Nihon Rinsho; 2002 Apr; 60(4):763-8. PubMed ID: 11968785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations.
    Mascolini M; Richman D; Larder B; Mellors J; Boucher CA
    Antivir Ther; 2008; 13(2):319-34. PubMed ID: 18505183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No residual activity of raltegravir after development of 148 complex mutations in vivo.
    Khanlou H; Sayana S; Acosta E
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.